These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 8949719

  • 21. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
    Toivonen P, Kivelä T.
    Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
    [Abstract] [Full Text] [Related]

  • 22. Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters.
    Mishra KK, Daftari IK, Weinberg V, Cole T, Quivey JM, Castro JR, Phillips TL, Char DH.
    Int J Radiat Oncol Biol Phys; 2013 Oct 01; 87(2):330-6. PubMed ID: 23886415
    [Abstract] [Full Text] [Related]

  • 23. Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumour height.
    Puusaari I, Damato B, Kivelä T.
    Graefes Arch Clin Exp Ophthalmol; 2007 Apr 01; 245(4):522-33. PubMed ID: 17111148
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma.
    Seregard S, Lundell G, Lax I, af Trampe E, Kock E.
    Acta Ophthalmol Scand; 1997 Apr 01; 75(2):148-54. PubMed ID: 9197561
    [Abstract] [Full Text] [Related]

  • 26. Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma.
    Yousef YA, Finger PT.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):1107-12. PubMed ID: 22172910
    [Abstract] [Full Text] [Related]

  • 27. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
    Heindl LM, Lotter M, Strnad V, Sauer R, Naumann GO, Knorr HL.
    Ophthalmologe; 2007 Feb 15; 104(2):149-57. PubMed ID: 17123048
    [Abstract] [Full Text] [Related]

  • 28. Estimates of ocular and visual retention following treatment of extra-large uveal melanomas by proton beam radiotherapy.
    Conway RM, Poothullil AM, Daftari IK, Weinberg V, Chung JE, O'Brien JM.
    Arch Ophthalmol; 2006 Jun 15; 124(6):838-43. PubMed ID: 16769837
    [Abstract] [Full Text] [Related]

  • 29. Factors predictive of radiation retinopathy post (125)Iodine brachytherapy for uveal melanoma.
    Krema H, Xu W, Payne D, Vasquez LM, Pavlin CJ, Simpson R.
    Can J Ophthalmol; 2011 Apr 15; 46(2):158-63. PubMed ID: 21708084
    [Abstract] [Full Text] [Related]

  • 30. Glaucoma After Iodine-125 Brachytherapy for Uveal Melanoma: Incidence and Risk Factors.
    Kim EA, Salazar D, McCannel CA, Kamrava M, Demanes DJ, Lamb J, Caprioli J, McCannel TA.
    J Glaucoma; 2020 Jan 15; 29(1):1-10. PubMed ID: 31688338
    [Abstract] [Full Text] [Related]

  • 31. Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases.
    Sagoo MS, Shields CL, Emrich J, Mashayekhi A, Komarnicky L, Shields JA.
    JAMA Ophthalmol; 2014 Jun 15; 132(6):697-702. PubMed ID: 24652552
    [Abstract] [Full Text] [Related]

  • 32. Reasons for enucleation after plaque radiotherapy for posterior uveal melanoma. Clinical findings.
    Shields CL, Shields JA, Karlsson U, Markoe AM, Brady LW.
    Ophthalmology; 1989 Jun 15; 96(6):919-23; discussion 924. PubMed ID: 2740084
    [Abstract] [Full Text] [Related]

  • 33. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy.
    Finger PT.
    Br J Ophthalmol; 2000 Sep 15; 84(9):1068-70. PubMed ID: 10966970
    [Abstract] [Full Text] [Related]

  • 34. Retina dose as a predictor for visual acuity loss in 106Ru eye plaque brachytherapy of uveal melanomas.
    Heilemann G, Fetty L, Blaickner M, Nesvacil N, Zehetmayer M, Georg D, Dunavoelgyi R.
    Radiother Oncol; 2018 Jun 15; 127(3):379-384. PubMed ID: 29452902
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma.
    Daftari IK, Char DH, Verhey LJ, Castro JR, Petti PL, Meecham WJ, Kroll S, Blakely EA.
    Int J Radiat Oncol Biol Phys; 1997 Dec 01; 39(5):997-1010. PubMed ID: 9392537
    [Abstract] [Full Text] [Related]

  • 37. Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience.
    Perri P, Fiorica F, D'Angelo S, Lamberti G, Parmeggiani F, Martini A, Carpenteri F, Colosimo C, Micucci M, Perazzini L, De Gugliemo E, Berretta M, Sebastiani A, Cartei F.
    Eur Rev Med Pharmacol Sci; 2012 Dec 01; 16(14):1919-24. PubMed ID: 23242717
    [Abstract] [Full Text] [Related]

  • 38. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
    Browne AW, Dandapani SV, Jennelle R, Stevanovic M, Lee TC, Murphree AL, Kampp TD, Astrahan MA, Kim JW, Berry JL.
    Brachytherapy; 2015 Dec 01; 14(5):718-25. PubMed ID: 26073224
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates.
    van Beek JGM, van Rij CM, Baart SJ, Yavuzyigitoglu S, Bergmann MJ, Paridaens D, Naus NC, Kiliç E.
    Acta Ophthalmol; 2022 Aug 01; 100(5):511-519. PubMed ID: 34529346
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.